Keywords
How to Cite
Abstract
The Authors provide an overview of useful treatments such as ‘Modified Mediterranean Diet’, CoQ10, melatonin, carnitine and ‘Quantum Therapy’, testing their effects in Type 2 Diabetes Mellitus (T2DM) primary prevention, performed possibly in the three first stages of T2DM. This is done through ‘Quantum Biophysical Semeiotics’ biological evaluation, clinically monitoring the results and efficiency of ongoing therapies aimed at improving mitochondrial and endothelial function, when it is impaired in any biological systems. This clinical method allows physicians to bedside assess tissue acidosis, before and during different preventive therapies, testing their respective efficacy and utility.
All the investigated treatments have firstly ameliorated and then normalized tissue microcirculatory pattern, showing a physiological functioning. Furthermore the tested ‘Quantum therapy’ generates virtuous genetic feedbacks.
‘Quantum Biophysical Semeiotics’ theory is an extension of medical semeiotics. It is grounded on a multidisciplinary approach that involves chemistry and biology, genetics and neuroscience, chaos theory and quantum physics.It is based on the method of ‘Auscultatory Percussion’, through which by means of the common stethoscope, it is possible to listen to the signs that the body gives us when appropriately stimulated.The stimuli are used to induce consistent behavior in precise and welldefined biological systems of the human body, thus giving local qualitative information on the state of health or disease, whether potential, being developed but not yet evident by usual clinical trial, effective or even in chronic phase. The 'Quantum Biophysical Semeiotics’ theory provides very detailed case studies based on the latency time, duration, and intensity of the reflexes, which play a central role in such a diagnostic method.
References
Stagnaro S, Caramel S. The Role of Mediterranean Diet, CoQ10 and Conjugated-Melatonin in Osteoporosis Primary Prevention and Therapy. Curr Nutr Food Sci 2012; 8: 55-62.
Stagnaro S. Istangiopatia Congenita Acidosica Enzimo-Metabolica. Una patologia mitocondriale ignorata. Gazz Med. It Arch Sci Med 1985; 144: 423.
Stagnaro S. Rivalutazione e nuovi sviluppi di un fondamentale metodo diagnostico: la percussione ascoltata. Atti Accademia Ligure di Scienze e Lettere 1978; Vol. XXXIV.
Stagnaro S. New Renaissance in Medicina. Type 2 Diabetes Mellitus Primary Prevention. First International Conference SISBQ, December 20th, 2010; Proceedings available at: http://www.sisbq.org
Stagnaro S. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I,
sottotipo a) oncologico, e b) aspecifico. Ed. Travel Factory, Roma 2009.
Stagnaro S, Stagnaro-Neri M. Le Costituzioni Semeiotico-Biofisiche. Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ed. Travel Factory, Roma 2004.
Caramel S, Stagnaro S. The role of mitochondria and mit-DNA in oncogenesis. Quantum Biosystems 2010; 2(1): 250-281.
Stagnaro S, Stagnaro-Neri M. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Ed. Travel Factory, Roma 2004.
Curri SB. Le Microangiopatie. Inverni della Beffa, Milano 1986.
Bucciante L. Anastomosi arterovenose e dispositivi regolatori del flusso sanguigno. Mon Zool It Suppl 1949; 57: 3-10.
Pratesi F. Microcircolazione e Microangiologia. Fisiopatologia, Clinica e Terapia. Ediz. Minerva Medica, Torino 1990.
Goldberger AL, West BJ. Applications of non-linear dynamics to clinical cardiology. Ann NY Acad Sci 1987; 504: 195.
http://dx.doi.org/10.1111/j.1749-6632.1987.tb48733.x
Stagnaro S, Stagnaro-Neri M. Deterministic chaotic biological system: the microcirculatory bed, Gazz. Med It-Arch Sci Med 1994; 153: 99.
Stagnaro S. Role of Coronary Endoarteriolar Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology 2007; Available at: http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php
Hammersen F. Zur ultrastruktur der arterio-veno¨sen anastomosen. In: Hammersen F, Gross D, Eds. Die Arterio-venoesen Anastomosen Anatomie, Physiologie, Pathologie, Klinik. Verlag Hans Hubert: Bern und Stuttgart 1968; pp. 24-37.
Caramel S. Primary Prevention of Type 2 Diabetes Mellitus, JOQBS, 2010; Available at: http://www.sisbq.org/uploads/5/ 6/8/7/5687930/t2dm_caramel.pdf
Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995; 16: 117-42.
Caramel S, Stagnaro S. Vascular calcification and Inherited Real Risk of lithiasis. Front. Endocrin 2012; 3: 119.
http://dx.doi.org/10.3389/fendo.2012.00119
Hsueh WA, Law ER. Pharmacological Treatment and Mechanisms of Insulin Resistance. In: Lipids and Syndromes of Insulin Resistance.From Molecula Biology to Clinical Medicine. Klimes I, Haffner SM, Sebokovà E, Howard BV, Storlien LH, Eds. Annals of the New York Academy of Sciences 1997; Vol. 827.
Stagnaro S, Stagnaro-Neri M. Stadio pre-ipertensivo e monitoraggio terapeutico della ipertensione arteriosa. Omnia Medica Therapeutica. Archivio 1989-90; 1990: 1-13.
Haffner SM, D’Agostino R Jr., Saad MF, et al. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared to non-Hispanic whites: The Insulin Resistance Atherosclerotic Study. Diabetes 1997; 46: 63-69.
http://dx.doi.org/10.2337/diabetes.46.1.63
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1995; 259(5091): 87-91.
http://dx.doi.org/10.1126/science.7678183
Kiesselbach A, Peiris AN, Evans DJ. Mechanisms associating body fat distribution to glucose intollerance and diabetes mellitus: window with a view. Acta Med Scand 1988; 723: 79-89.
Opie EL. The relation of diabetes mellitus to lesions of pancreas: hyaline degeneration of the islands of Langherans. J Exp Med 1901; 5: 52-40.
Westermark P, Wernstedt C, Wilander E, Sletten A. A novel peptide in the calcitonin gene related peptide familyas an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140: 827-31.
http://dx.doi.org/10.1016/0006-291X(86)90708-4
Hoeppener VWM, Ahren B. Islet Amiloid and Type 2 Diabetes Mellitus. N Engl J Med 2000; 6: 411-19.
Stagnaro S, Stagnaro-Neri M. Valutazione percusso-ascoltatoria del Diabete Mellito. Aspetti teorici e pratici. Epat 1986; 32: 131.
Stagnaro S, Stagnaro-Neri M. Sindrome di Reaven, classica e variante, in evoluzione diabetica. Il ruolo della Carnitina nella prevenzione del diabete mellito. Il Cuore 1993; 6: 617.
Harris MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 1993; 16: 642-52.
Stagnaro S, Stagnaro-Neri M, Single Patient Based Medicine. La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory, Roma 2005; http://www.travelfactory.it/
Stagnaro S. Pre-Metabolic Syndrome and Metabolic Syndrome: Biophysical-Semeiotic Viewpoint. www.athero. org, April, 2009; http://www.athero.org/commentaries/ comm904.asp
Stagnaro S. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr 2007; [Epub ahead of print] [Medline].
http://dx.doi.org/10.1038/sj.ejcn.1602668
Stagnaro S. Biophysical-Semeiotic Diabetic Constitution. Cyber Lecture, www.indmedica.com, 2006; http://cyberlectures.indmedica.com/show/60/1/Diabetic_Constitution
Stagnaro S. Biophysical-Semeiotic Dyslipidaemic Constitution. Cyber Lecture, www.indmedica.com, 2006; http://cyberlectures.indmedica.com/show/50/1/Biophysical-Semeiotic_Dyslipidaemic_Constitution
Stagnaro S, Caramel S. Dyslipidaemia Constitution 2010; Available at: http://www.sisbq.org/uploads/5/6/8/7/5687930/ dyslipidaemia_caramel.pdf
Stagnaro S, Stagnaro-Neri M. Valutazione percusso-ascoltatoria del Diabete Mellito. Aspetti teorici e pratici. Epat 1986; 32: 131.
Stagnaro S, Stagnaro-Neri M. Il Segno di Bilancini-Lucchi nella diagnosi clinica del diabete mellito. Pract Ed It 1993; 176: 30.
Stagnaro-Neri M, Stagnaro S. Auscultatory Percussion Evaluation of Arterio-venous Anastomoses Dysfunction in early Arteriosclerosis. Acta Med Medit 1989; 5: 141-44.
Stagnaro-Neri M, Stagnaro S. Diagnosi Clinica Precoce dell’Osteoporosi con la Percussione Ascoltata. Clin Ter 1991; 137: 21-27.
Stagnaro S. Siniscalchi’s Sign*. Bedside Recognizing, in one Second, Diabetic Constitution, its Inherited Real Risk, and Type 2 Diabetes Mellitus. JOQBS, 2010. Available at: http://www.sisbq.org/uploads/5/6/8/7/5687930/siniscalchi_sign.pdf
InterAct Consortium, Romaguera D, Guevara M, et al. Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project. Diabetes Care 2011; 34(9): 1913-8.
http://dx.doi.org/10.2337/dc11-0891
Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. PREDIMED Study Investigators. Diabetes Care 2011; 34(1): 14-9.
Trichopoulou A. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ 2005; 330: 991. doi:10.1136/bmj.38415.644155.8F; published April 2005.
Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433-9.
http://dx.doi.org/10.1001/jama.292.12.1433
Esposito K, Maiorino MI, Ceriello A, et al. Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. Diabetes Res Clin Pract 2010; 89(2): 97-102.
http://dx.doi.org/10.1016/j.diabres.2010.04.019
Basterra-Gortari FJ, Martínez-González MA. Mediterranean diet in type 2 diabetes. Diabetologia 2008; 51(10): 1933-4.
http://dx.doi.org/10.1007/s00125-008-1121-x
Martínez-González MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 2008; 336(7657): 1348-51.
http://dx.doi.org/10.1136/bmj.39561.501007.BE
Salas-Salvadó J, Martinez-González MÁ, Bulló M, Ros E. The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 2011; 21(Suppl 2): B32-48.
http://dx.doi.org/10.1016/j.numecd.2011.03.009
Stagnaro S, West PJ, Hu FB, Manson JE, Willett WC. Diet and Risk of Type 2 Diabetes. N Engl J Med 2002; 346(4): 297-98.
http://dx.doi.org/10.1056/NEJM200201243460418
Stagnaro-Neri M, Stagnaro S. Acidi grassi -3, scavengers dei radicali liberi e attivatori del ciclo Q della sintesi del CoQ10. Gazz Med It– Arch Sc Med 1992; 151: 341-45.
Lenaz G, Parenti Castelli G. Multiple roles of ubiquinone in mammalians cells. Drugs Exptl Clin Res 1984; 10: 481-85.
Lubich T, Bargossi AM, Fiorella PL. Metabolic effects of coenzyme Q treatment in high level athletes. VI Simposio Internazionale su: Biomedical and clinical aspects of coenzyme Q. Chairmen: Folkers K, Littarru GP, Yamagamy Y. 22-24 gennaio 1990, Roma. Abstracts, 70.
Persson MF, Franzén S, Catrina SB, et al. Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia 2012; 55(5): 1535-43.
http://dx.doi.org/10.1007/s00125-012-2469-5
Sourris KC, Harcourt BE, Tang PH, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2012; 52(3): 716-23.
http://dx.doi.org/10.1016/j.freeradbiomed.2011.11.017
Stagnaro S, Stagnaro-Neri M. Carenza di CoQ10 secondaria a terapia ipolipidemizzante diagnosticata con la percussione ascoltata. Settimana Italiana di Dietologia. Merano 9-13 aprile 1990. Com.. Abstract. 105 e Epatol 1991; 37: 17-22.
Stagnaro-Neri M, Stagnaro S. Auscultatory Percussion Coenzyme Q deficiency Syndrome. VI Simposio Internazionale su: Biomedical and clinical aspects of coenzyme Q. Chairmen: Folkers K, Littarru GP, Yamagamy Y, 22-24 gennaio 1990, Roma. Abstracts, 104.
Stagnaro S. Ipercolesterolemia e Coenzima Q10. Pract Ed. It 1990; 133: 5-6.
Stagnaro-Neri M, Stagnaro S. Sindrome clinica percusso-ascoltatoria da carenza di Co Q10. Medic Geriatr 1993; XXIV: 239-51.
Mitchel P. The vital protonmotive role of Coenzyme Q. VI Simposio Internazionale su: Biomedical and clinical aspects of coenzyme Q. Chairmen: Folkers K, Littarru GP, Yamagamy Y, gennaio 1990, Roma. Abstracts, 77.
Neri Stagnaro M, Stagnaro S. CoQ10 in the prevention and treatment of primary osteoporosis. Preliminary data. Clin Ter 1995; 146(3): 215-9.
Gutierrez-Mariscal FM, Perez-Martinez P, Delgado-Lista J, et al. Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to oxidative DNA damage in elderly subjects. Age (Dordr) 2012; 34(2): 389-403.
http://dx.doi.org/10.1007/s11357-011-9229-1
Ochoa JJ, Pamplona R, Ramirez-Tortosa MC, et al. Age-related changes in brain mitochondrial DNA deletion and oxidative stress are differentially modulated by dietary fat type and coenzyme Q₁₀. Free Radic Biol Med 2011; 50(9): 1053-64.
http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.004
Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010; 16(2): 183-8.
http://dx.doi.org/10.1002/ddrr.108
Sourris KC, Harcourt BE, Tang PH, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2012.
http://dx.doi.org/10.1016/j.freeradbiomed.2011.11.017
Takahashi R. Anti-aging studies on the senescence accelerated mouse (SAM) strains. Yakugaku Zasshi 2010; 130(1): 11-8.
http://dx.doi.org/10.1248/yakushi.130.11
Stagnaro S, Stagnaro-Neri M. La Melatonina nella Terapia del Terreno Oncologico e del “Reale Rischio” Oncologico. Ed. Travel Factory, Roma 2004.
Stagnaro S. Endothelial cell function can ameliorate under safer drugs, such as Melatonin-Adenosine. BMC Cardiovascular disorders. 2004; Available at: http://www.biomedcentral.com/1471-2261/4/4/comments
Carpentieri A, Díaz de Barboza G, Areco V, Peralta López M, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res 2012.
http://dx.doi.org/10.1016/j.phrs.2012.01.003
Espino J, Pariente JA, Rodríguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes 2011; 2(6): 82-91.
http://dx.doi.org/10.4239/wjd.v2.i6.82
Zavodnik IB, Lapshina EA, Cheshchevik VT, et al. Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes. J Physiol Pharmacol 2011; 62(4): 421-7.
Qiu XF, Li XX, Chen Y, et al. Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats. Asian J Androl 2012; 14(3): 481-6.
http://dx.doi.org/10.1038/aja.2011.161
Stagnaro S. Il test Semeiotico-Biofisico della Osteocalcina nella prevenzione primaria del diabete mellito, 2008; Available at: http://www.fcenews.it/index.php?option= com_content&task=view&id=909&Itemid=47
Davis PF, Barbee KA. Hemodynamics and Atherogenesis. Endothelial Surface Dynamics in Flow Signal Transuction. Recent Advances in Atherosclerosis Research. Ann NY Acad Sci 1995; 748: 86-103.
http://dx.doi.org/10.1111/j.1749-6632.1994.tb17310.x
Stagnaro-Neri M, Stagnaro S. Sindrome di Reaven, classica e variante, in evoluzione diabetica. Il ruolo della Carnitina nella prevenzione del diabete mellito. Il Cuore 1993; 6: 617.
Stagnaro-Neri M, Stagnaro S. La sindrome percusso-ascoltatoria da carenza di Carnitina. Clin Ter 1994; 145: 135.
Stagnaro-Neri M, Stagnaro S. Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med Medit 1997; 13: 125.
Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr 2012; 51(1): 1-18.
http://dx.doi.org/10.1007/s00394-011-0284-2
Tamamoğullari N, Siliğ Y, Içağasioğlu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999; 13(5-6): 251-3.
http://dx.doi.org/10.1016/S1056-8727(99)00052-5
Kozhemyakin A. Report on Clinical Evaluation for EHF – IR therapies device portable with changeable oscillators “Cem Tech”. Spinor O’LTD, 2008. Available at: http://www. schungit-mineralien.de/CEM-TECH/docs/Ergebnisse-klinik-eng.pdf
Stagnaro S, Caramel S. The role of Modified Mediterranean Diet and Quantum Therapy in Oncological Primary Prevention. Curr Nutr Food Sci 2013; 9: (in press).
Caramel S. Meccanismi d’azione sconosciuti dell’acqua termale sulfurea. JOQBS, 2012; Available at: http://www.sisbq.org/uploads/5/6/8/7/5687930/h2s.pdf
Stagnaro S, Caramel S. A new way of therapy based on water memory information: the quantum biophysical approach, JOQBS, 2011; Available at: http://www.sisbq.org/ uploads/5/6/8/7/5687930/qbtherapy.pdf
Stagnaro S, Caramel S. The genetic reversibility in Oncology. JOQBS, 2011; Available at: http://www.sisbq.org/uploads/5/ 6/8/7/5687930/reverse_oncology.pdf
Pellionsz AJ. The principle of recursive genome function. Cerebellum (Springler Verlag), 2008; 7. Available at: http://junkdna.com/pellionisz_principle/pellionisz_principle_from_web.pdf
Pellionisz AJ, Graham R, Pellionisz PA, Perez JC. Recursive genome function of the cerebellum: geometric unification of neuroscience and genomics. Chapter in Handbook: “The Cerebellum and cerebellar disorders” Ed. Dr. Mario Manto, Springer Verlag 2011.
Stagnaro S, Caramel S. The principle of recursive genome function: QBS clinical and experimental evidences. JOQBS, 2011; Available at: http://www.sisbq.org/uploads/5/6/8/7/ 5687930/prgf_qbsevidences.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2013 Sergio Stagnaro, Simone Caramel